[Editor's Note: This article has been updated with additional commentary from Pieter Kappetein, Chief Medical Officer for Medtronic’s structural heart business.]
Medtronic PLC is sponsoring a feasibility study of its Intrepid transcatheter mitral valve replacement system delivered through the transfemoral approach in patients with severe,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?